2
Views
0
CrossRef citations to date
0
Altmetric
Ethical Perspective

Suggested ethical guidelines and legislation for egg donation in Singapore

Pages 181-188 | Published online: 10 Jan 2014

References

  • Ramsey J. Donating eggs for research – should the HFEA reconsider its policy on payments to egg donors? Reprod. Biomed. Online15(Suppl. 1), 25–33 (2007).
  • Roberts C, Throsby K. Paid to share: IVF patients, eggs and stem cell research. Soc. Sci. Med.66(1), 159–169 (2008).
  • Robertson JA. Compensation and egg donation for research. Fertil. Steril.86(6), 1573–1575 (2006).
  • Covington SN, Gibbons WE; Society for Assisted Reproductive Technology. What is happening to the price of eggs? Fertil. Steril.87(5), 1001–1004 (2007).
  • Heng BC. Alternative solutions to the current situation of oocyte donation in Singapore. Reprod. Biomed. Online12(3), 286–291 (2006).
  • Pennings G, Devroey P. Subsidized in-vitro fertilization treatment and the effect on the number of egg sharers. Reprod. Biomed. Online13(1), 8–10 (2006).
  • Heng BC, Zhang X. Perspectives on compensated egg-sharing in the People’s Republic of China. Reprod. Biomed. Online14(5), 664–665 (2007).
  • Heng BC. International egg-sharing to provide donor oocytes for clinical assisted reproduction and derivation of nuclear transfer stem cells. Reprod. Biomed. Online11(6), 676–678 (2005).
  • Blyth E. Subsidized IVF: the development of ‘egg sharing’ in the United Kingdom. Hum. Reprod.17(12), 3254–3259 (2002).
  • Blyth E. Patient experiences of an ‘egg sharing’ programme. Hum. Fertil. (Camb.)7(3), 157–162 (2004).
  • Rasmussen C. Canada’s Assisted Human Reproductive Act: is it scientific censorship, or a reasoned approach to the regulation of rapidly emerging reproductive technologies? Sask. Law Rev.67(1), 97–135 (2004).
  • Heng BC. Ethical issues in paying for long-distance travel and accommodation expenses of oocyte donors. Reprod. Biomed. Online11(5), 552–553 (2005).
  • Heng BC. Regulatory safeguards needed for the travelling foreign egg donor. Hum. Reprod.22(8), 2350–2352 (2007).
  • Schneider I. Oocyte donation for reproduction and research cloning – the perils of commodification and the need for European and international regulation. Law Hum. Genome Rev.25, 205–241 (2006).
  • Norsigian J. Egg donation dangers: additional demand for eggs leads to additional risks. Genewatch18(5), 6–8 (2005).
  • Ahuja KK, Simons EG, Edwards RG. Money, morals and medical risks: conflicting notions underlying the recruitment of egg donors. Hum. Reprod.14(2), 279–284 (1999).
  • Pennings G, de Wert G et al. ESHRE Task Force on Ethics and Law; ESHRE Task Force on Ethics and Law 12, oocyte donation for non-reproductive purposes. Hum. Reprod.22(5), 1210–1213 (2007).
  • Steinbock B. Payment for egg donation and surrogacy. Mt Sinai J. Med.71(4), 255–265 (2004).
  • International Stem Cell Forum Ethics Working Party. Oocyte donation for stem cell research. Science316(5823), 368–370 (2007).
  • Craft I, Thornhill A. Would ‘all-inclusive’ compensation attract more gamete donors to balance their loss of anonymity? Reprod. Biomed. Online10(3), 301–306 (2005).
  • Thompson C. Why we should, in fact, pay for egg donation. Regen. Med.2(2), 203–209 (2007).
  • Hyun I. Fair payment or undue inducement? Nature442(7103), 629–630 (2006).
  • Dornbusch R. Exchange rates and prices. American Economic Review77(1), 93–106 (1987).
  • Justice HM, Counselman FL. Ovarian hyperstimulation syndrome: an important complication of in vitro fertilization. Am. J. Emerg. Med.26(1), e3–e4 (2008).
  • Budev MM, Arroliga AC, Falcone T. Ovarian hyperstimulation syndrome. Crit. Care Med.33(10 Suppl.), S301–S306 (2005).
  • Pearson H. Health effects of egg donation may take decades to emerge. Nature442(7103), 607–608 (2006).
  • Spar D. The egg trade – making sense of the market for human oocytes. N. Engl. J. Med.356(13), 1289–1291 (2007).
  • ESHRE Task Force on Ethics and Law III. Gamete and embryo donation. Hum. Reprod.17, 1407–1408 (2002).
  • Heng BC. Patients, instead of medical professionals, should directly reimburse egg donors for their time, inconvenience and potential loss of earnings. Expert Rev. Obstet. Gynecol.2(2), 121–122 (2007).
  • Baetens P, Devroey P, Camus M, Van Steirteghem AC, Ponjaert-Kristoffersen I. Counselling couples and donors for oocyte donation: the decision to use either known or anonymous oocytes. Hum. Reprod.15(2), 476–484 (2000).
  • Dimond B. Law concerning organ transplants and dead donors in the UK. Br. J. Nurs.14(1), 47–48 (2005).
  • Samuels A. Human Tissue Act 2004, the removal and retention of human organs and tissue. Med. Leg. J.72(Pt 4), 148–150 (2004).
  • Heng BC. Legal and ethical issues in the international transaction of donor sperm and eggs. J. Assist. Reprod. Genet.24(4), 107–109 (2007).
  • Heng BC. The advent of international ‘mail-order’ egg donation. BJOG113(11), 1225–1227 (2006).
  • Mertes H, Pennings G. Oocyte donation for stem cell research. Hum. Reprod.22(3), 629–634 (2007).
  • The Ethics Committee Of The American Society For Reproductive Medicine. Financial compensation of oocyte donors. Fertil. Steril.88(2), 305–309 (2007).
  • The Practice Committee of the American Society for Reproductive Medicine; Practice Committee of the Society for Assisted Reproductive Technology. Ovarian tissue and oocyte cryopreservation. Fertil. Steril.86(Suppl. 5), S142–S147 (2006).
  • Shaw JM, Oranratnachai A, Trounson AO. Fundamental cryobiology of mammalian oocytes and ovarian tissue. Theriogenology53, 59–72 (2000).
  • Baka SG, Toth TL, Veeck LL, Jones HW Jr, Muasher SJ, Lanzendorf SE. Evaluation of the spindle apparatus of in-vitro matured human oocytes following cryopreservation. Hum. Reprod.10, 1816–1820 (1995).
  • Matson PL, Graefling J, Junk SM, Yovich JL, Edirisinghe WR. Cryopreservation of oocytes and embryos: use of a mouse model to investigate effects upon zona hardness and formulate treatment strategies in an in-vitro fertilization programme. Hum. Reprod.12, 1550–1553 (1997).
  • Ridley DB. Price differentiation and transparency in the global pharmaceutical marketplace. Pharmacoeconomics23, 651–658 (2005).
  • Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int. J. Health Care Finance Econ.3, 183–205 (2003).
  • Frank RG. Prescription drug prices: why do some pay more than others do? Health Aff. (Millwood)20, 115–128 (2001).
  • Glass G. Pharmaceutical patent challenges: time for reassessment? Nat. Rev. Drug Discov.3(12), 1057–1062 (2004).
  • Attaran A. How do patents and economic policies affect access to essential medicines in developing countries? Health Aff. (Millwood)23(3), 155–156 (2004).
  • Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science (2007) (Epub ahead of print).
  • Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell131(5), 861–872 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.